Related by context. All words. (Click for frequent words.) 76 randomized 75 randomized #:#:# 67 blind randomized 67 mg BID 66 blind randomized placebo 66 randomly assigned 66 blinded placebo controlled 66 #mg QD [002] 66 saline placebo 65 administered subcutaneously 65 treatment naive genotype 65 mg QD 65 mcg kg 65 multicenter randomized 65 stage IIIB 65 randomized multicenter 65 #mg/m# [001] 65 pegylated interferon alfa 2a 65 dose dose escalation 65 evaluable 65 Phase III randomized 65 active comparator 65 blind placebo 64 Pegasys ® 64 8mg/kg 64 dacarbazine 64 4mg/kg 64 ritonavir boosted 64 ascending doses 64 placebo controlled randomized 64 masked placebo controlled 64 interferon alfa 2a 64 multicenter randomized placebo controlled 64 lopinavir r 64 refractory NSCLC 64 nab paclitaxel 64 double blinded placebo 64 multicenter randomized double 64 ascending dose 63 mcg albinterferon alfa 2b 63 controlled multicenter 63 randomized placebo controlled 63 PREZISTA r 63 #mg/m# [002] 63 treatment naïve genotype 63 dosing cohorts 63 unresectable stage 63 TMC# C# 62 Copegus ® ribavirin 62 label multicenter 62 relapsed MM 62 relapsed refractory multiple myeloma 62 prospective multicenter randomized 62 prospective randomized 62 blind multicenter 62 μg dose 62 peginterferon alfa 2b 62 PREZISTA ritonavir 62 HBeAg positive 62 multicenter Phase III 62 FOLFOX 62 multicentre randomized double 62 label dose escalation 62 BRIM2 62 plus ribavirin 62 weekly subcutaneous injections 62 dosing cohort 62 pegylated interferon alfa 2b 62 randomized double 62 VELCADE melphalan 62 chlorambucil 62 blinded randomized 62 prospective randomized placebo 62 certolizumab 62 plus dexamethasone 61 prospectively defined 61 pegylated interferon 61 mg TID 61 telaprevir dosed 61 multicentre randomized 61 APTIVUS r 61 erlotinib Tarceva ® 61 multicenter randomized controlled 61 dosage regimens 61 intravitreal injection 61 nonrandomized 61 Peg IFN 61 continuous intravenous infusion 61 mg RDEA# 61 dose cohorts 61 abacavir lamivudine 61 subcutaneously administered 61 n = 61 vinorelbine 61 ribavirin RBV 61 dose escalation study 61 Randomized 61 EURIDIS 61 melphalan prednisone 61 mg administered orally 61 peginterferon alfa 2a Pegasys 61 prospective multicenter 61 metastatic renal cell carcinoma 61 ACTEMRA TM 61 #mg BID [003] 61 randomized controlled 61 evaluable patients 61 #:# randomization 61 comparing XIENCE V 61 atazanavir ritonavir 61 telaprevir dosing 61 Traficet EN 61 #mg/kg [002] 60 QD dosing 60 phase IIb clinical 60 ug dose 60 plus prednisone 60 dose escalation trial 60 placebo controlled Phase III 60 Phase 1a 60 placebo controlled 60 intradermal injections 60 carboplatin paclitaxel 60 Phase 1b 60 double blind placebo 60 de novo kidney transplant 60 placebo controlled Phase 60 galiximab 60 5-FU/LV 60 mRCC 60 mg kg dose 60 double blinded randomized 60 mg/m2 dose 60 HCV RESPOND 2 60 AIR CF1 60 blinded randomized placebo controlled 60 stage IIIb IV 60 peg IFN 60 rapid virologic response 60 alfa 2a 60 docetaxel Taxotere ® 60 docetaxel chemotherapy 60 placebo intravenously 60 Pharmacokinetics PK 60 Pegasys plus Copegus 60 diagnosed GBM 60 ritonavir boosted atazanavir 60 randomized blinded 60 comparator arm 60 q#h 60 CsA 60 evaluable subjects 60 REYATAZ r arm 60 Peginterferon 60 adalimumab 60 irbesartan 60 subcutaneous injections 60 mg/m2 60 Phase 2b study 60 safety tolerability pharmacokinetics 60 blind randomized controlled 60 randomized Phase III 60 dose regimens 60 interferon alfa 2b 59 lopinavir r arm 59 HCV SPRINT 59 mcg BID 59 mg qd 59 insulin detemir 59 low dose cytarabine 59 dacarbazine DTIC 59 Primary endpoints 59 Phase Ib 59 alpha 2b 59 symptomatic BPH 59 recurrent glioblastoma multiforme 59 huN# DM1 59 Initiate Phase 59 tenofovir emtricitabine 59 Randomised 59 monotherapy 59 darunavir ritonavir 59 sirolimus eluting stents 59 blinded placebo 59 neoadjuvant 59 FOLFOX4 59 diagnosed multiple myeloma 59 primary hypercholesterolemia 59 trastuzumab Herceptin R 59 daunorubicin 59 randomized multicentre 59 dasatinib Sprycel ® 59 prospective randomized multicenter 59 Platinol ® cisplatin 59 evaluating tivozanib 59 peginterferon alfa 2a 59 mg ustekinumab 59 TAXOTERE R 59 naïve HCV 59 IV bolus 59 metastatic HRPC 59 dose cohort 59 PegIFN 59 antiretroviral naive 59 prospective randomized controlled 59 dose escalation phase 59 estramustine 59 LEXIVA r 59 #.#mg/dL 59 CML CP 59 non splenectomized 59 Q2W 59 pegaptanib 59 stable angina pectoris 59 FOLFIRI 59 subcutaneous doses 59 multiple ascending dose 59 NOXAFIL Oral Suspension 59 plus methotrexate 59 single ascending dose 59 daily Infergen 59 dose escalation 59 relapsed myeloma 59 pharmacokinetics PK 59 Fludara 59 Phase IIIb 59 IV NSCLC 58 histologically confirmed 58 HCV genotype 1 58 5mg/kg 58 placebo dexamethasone 58 mg d 58 Phase Ib II 58 tenecteplase 58 CHOP chemotherapy 58 peginterferon alfa 2a #KD 58 unfractionated heparin UFH 58 randomized multicenter trial 58 Phase Ib clinical 58 Amrubicin 58 CIMZIA TM 58 Taxotere ® 58 daily subcutaneous injections 58 bosentan 58 label dose titration 58 ribavirin therapy 58 CTA# Injection 58 Phase 2b randomized 58 NSABP B 58 3TC lamivudine Epivir 58 peginterferon alfa 58 pegylated interferon alpha 58 RG# [001] 58 blind randomized multicenter 58 HGS ETR1 58 #mg q8h 58 multicenter clinical 58 achieved ACR# 58 REVIVE Diabetes 58 golimumab CNTO 58 piperacillin tazobactam 58 dose titration 58 ongoing Phase 1b 58 chronic HCV 58 antiretroviral naïve 58 gemcitabine carboplatin 58 mcg QD 58 achieved PASI 58 bendamustine 58 docetaxel Taxotere R 58 intravenous bolus 58 sunitinib malate 58 placebo 58 REVLIMID lenalidomide 58 multicenter multinational 58 virologic failure 58 receptor tyrosine kinase inhibitor 58 metastatic GIST 58 sirolimus eluting stent 58 mg subcutaneously 58 prospectively randomized 58 sorafenib Nexavar ® 58 mcg linaclotide 58 plus gemcitabine 58 KRAS mutations occur 58 injected subcutaneously 58 Randomized Phase II 58 undetectable HCV RNA 58 OADs 58 placebo controlled clinical 58 5 fluorouracil leucovorin 58 DU #b 58 budesonide pMDI 58 adjunctive placebo 58 HCV Genotype 58 blind placebo controlled 58 undetectable HBV DNA 58 Contrave# 58 recurrent NSCLC 58 randomized clinical 58 mg q#h 58 efavirenz EFV 58 TELCYTA 58 chemoradiation therapy 58 multicenter Phase 58 adefovir 58 dose cytarabine 58 unresectable HCC 58 Allovectin 7 ® 58 RRMS patients 58 PEG IFN 57 Monotherapy 57 SCH # 57 unresectable 57 refractory multiple myeloma 57 Treatment Experienced 57 visilizumab 57 mitomycin C 57 relapsing multiple sclerosis 57 dose pharmacokinetic 57 #mg/day [001] 57 assessing T DM1 57 Randomized Double Blind Placebo 57 infliximab monotherapy 57 DAPT 57 Thrombolysis 57 PegIFN RBV 57 XIENCE V PROMUS Stent 57 FOLFOX6 57 patients evaluable 57 TMC# r 57 multicenter 57 docetaxel prednisone 57 pegylated interferon alpha 2a 57 placebo controlled dose escalation 57 metformin sulfonylurea 57 APTIVUS 57 subcutaneous dose 57 PREZISTA rtv 57 Omacetaxine mepesuccinate 57 phase IIb 57 dyskinesia PD LID 57 gemcitabine 57 naive HCV 57 randomized controlled Phase 57 Pivotal Phase 57 tacrolimus ointment 57 Phase IIIb clinical 57 HER2 positive metastatic breast 57 viral kinetics 57 PEGASYS ® 57 mcg doses 57 Oral Fingolimod 57 mg dose 57 evaluating REVLIMID 57 Trial Evaluating 57 Phase III randomized controlled 57 #mg BID [001] 57 placebo PBO 57 GetGoal Phase III 57 Zyclara 57 Pegasys R 57 3mg/kg 57 mcg dose 57 Panzem R NCD 57 oral rivaroxaban 57 methotrexate monotherapy 57 Initiated Phase 57 lanthanum carbonate 57 receiving highly emetogenic 57 biochemical relapse 57 posaconazole 57 DLTs 57 intramuscularly 57 dosed orally 57 Randomized Evaluation 57 PEGINTRON TM 57 colesevelam HCl 57 designated HVTN 57 Myocardial Infarction Study 57 NSTE ACS 57 Phase 1b clinical 57 microgram kg 57 flutamide 57 phase IIb study 57 IMPACT DCM trial 57 sorafenib tablets 57 Kinesin Spindle Protein KSP 57 emtricitabine tenofovir 57 events AEs 57 mg orally 57 calcineurin inhibitor 57 dose escalation clinical 57 superficial bladder cancer 57 bevacizumab Avastin ® 57 CANCIDAS 57 ARIXTRA 57 R# #mg BID 57 azathioprine 57 Diffuse Large B 57 ARIKACE 57 PegIntron 57 unblinded 57 unique alkylating agent 57 FOLFIRI alone 57 Phase 2b 56 Relapsed Refractory 56 urinary N telopeptide 56 dose escalation Phase 56 azacitidine 56 HBeAg negative patients 56 multicenter prospective 56 partial remissions 56 refractory CLL 56 Phase 2b clinical 56 antithymocyte globulin 56 Folfox 56 temsirolimus 56 metastatic RCC 56 EDEMA3 56 BRIM3 56 intravenous dosing 56 dependent kinase inhibitor 56 CorVue ™ 56 peginterferon 56 phase Ib 56 dosing regimens 56 pegylated alpha interferon 56 subcutaneous formulation 56 metastatic CRC 56 Pivotal Trial 56 Randomized Phase 56 timepoint 56 Phase #/#a 56 eosinophilic asthma 56 Pivotal Phase III 56 ARB telmisartan 56 severe neutropenia 56 HCV infected 56 Newly Diagnosed Multiple Myeloma 56 Peginterferon Alfa 2a 56 cells mcL 56 ZYBRESTAT fosbretabulin 56 ALT flares 56 TAXUS ATLAS 56 Stage IIIb 56 Naive Patients 56 paclitaxel poliglumex 56 phase IIa 56 AVOREN 56 interferon gamma 1b 56 plus Copegus R 56 Elotuzumab 56 oral vancomycin 56 resectable 56 Anti VEGF 56 concurrent chemoradiation 56 HBeAg + 56 IFN alfa 56 ceftazidime 56 GW# [003] 56 multicentre 56 μg kg 56 trials RCTs 56 docetaxel 56 sunitinib 56 ASCT 56 null responder HCV 56 romiplostim 56 mg kg 56 huC# DM4 56 FOLFOX4 alone 56 multicenter Phase II 56 HGS ETR1 mapatumumab 56 FOLPI 56 pegylated interferon peg IFN 56 prospectively stratified 56 dalteparin 56 #.#mg/kg [002] 56 Placebo controlled 56 REYATAZ r 56 Xanafide 56 relapsed refractory ALL 56 RE LY ® 56 adefovir treated 56 Albuferon TM 56 IL# PE#QQR 56 HGS ETR2 56 DEB# 56 lymphoid blast 56 patients undergoing percutaneous 56 label multicenter Phase 56 insulin glulisine 56 mg/m2/day 56 plus COPEGUS 56 sirolimus eluting 56 clodronate 56 nucleoside analog 56 TORISEL 56 oral levofloxacin 56 metastatic CRPC 56 inhalations twice 56 Capecitabine 56 VIRAMUNE XR 56 fallopian tube carcinoma 56 Randomized Double Blind 56 CLL8 56 MIRCERA 56 tirofiban 56 olmesartan 56 safety tolerability 56 Cloretazine 56 Recurrent Glioblastoma 56 TDF FTC 56 APTIVUS ritonavir 56 oral ridaforolimus 56 beta2 agonist 56 randomized controlled multicenter 56 paclitaxel eluting stents 56 salmeterol fluticasone 56 Ceplene/IL-2 56 TMC# [001] 56 platinum refractory 56 prior chemotherapy regimens 56 mg/m2 IV 56 CAELYX 56 CIMZIA R 56 fallopian tube cancers 56 #mg BID [002] 56 achieved statistical significance 56 bolus injection 56 q8h 56 label multicenter randomized 56 intra articular injection 56 refractory metastatic colorectal cancer 56 mg subcutaneous 56 #mg QD [001] 56 FOLFOX6 chemotherapy regimen 56 mCi kg 56 Augment Injectable 56 pegylated liposomal doxorubicin 56 myelofibrosis MF 56 log# IU mL 56 octreotide LAR 56 VICTOR E1 56 Phase III Clinical Trial 56 lispro 55 zonisamide SR 55 candesartan cilexetil 55 Adalimumab 55 rilonacept 55 relapsed multiple myeloma 55 LPV r 55 Neovascular AMD 55 ROCKET AF 55 Phase Ia 55 BR.# 55 Phase Ib clinical trials 55 factorial design 55 colorectal liver metastases 55 Copegus ribavirin 55 adriamycin 55 nitazoxanide 55 dapagliflozin plus 55 glycoprotein IIb IIIa inhibitor 55 Patients Treated 55 Secondary endpoints 55 nonresponders 55 nucleoside reverse transcriptase inhibitor 55 fludarabine 55 idarubicin 55 REBETOL 55 TO AVOID PREGNANCY WHILE 55 TMC# [002] 55 Hepatitis C Patients 55 metastatic hormone refractory 55 CLL SLL 55 lumbar spine BMD 55 desvenlafaxine succinate 55 vicriviroc 55 cilengitide 55 oblimersen 55 CMV seropositive 55 Metastatic Prostate Cancer 55 Flu Cy 55 plus glycoprotein IIb 55 fludarabine cyclophosphamide 55 chronic HCV genotype 55 Phase IIB 55 Pemetrexed 55 Tarceva TM 55 systemically administered 55 lymphoma CTCL 55 EFAPROXYN 55 decitabine 55 paclitaxel carboplatin 55 Aflibercept 55 dose dexamethasone 55 TACE 55 PEGylated interferon beta 1a 55 Laquinimod 55 dexamethasone Decadron 55 randomized Phase IIb 55 non inferiority 55 COU AA 55 beclomethasone dipropionate 55 virological failure 55 plasma HCV RNA 55 thrombocytopenic patients 55 controlled dose escalation 55 Phase IIb 55 heavily pretreated patients 55 SELZENTRY 55 phase IIa clinical 55 nicardipine 55 recurrent malignant glioma 55 mcg 55 bortezomib Velcade R 55 oral sapacitabine 55 peginterferon alpha 2a 55 weekly intravenous infusions 55 pegylated interferon alfa 55 Relapsed 55 unfractionated heparin 55 NPH insulin 55 dacarbazine chemotherapy 55 nucleoside naive 55 imatinib resistant 55 Decitabine 55 alvespimycin 55 follicular NHL 55 Methylnaltrexone 55 viral kinetic 55 randomized controlled clinical 55 splenectomized 55 Phase 2b trial 55 recurrent GBM 55 TYKERB 55 subcutaneously 55 serum phosphorus 55 metastatic malignant melanoma 55 fosbretabulin 55 intravitreal injections 55 SCIg 55 EVIZON 55 Placebo Controlled 55 generation purine nucleoside 55 Taxotere R 55 Hepatocellular Carcinoma HCC 55 sustained virological response 55 MabCampath 55 Meets Primary Endpoint 55 pharmacodynamic PD 55 lubiprostone 55 mg kg hr 55 biliary tract cancer 55 tolerated dose MTD 55 EGFR TKI 55 COPEGUS ribavirin 55 REVLIMID ® 55 oral allopurinol 55 Cutaneous T 55 chemoradiotherapy 55 xanthine oxidase inhibitor 55 evaluating picoplatin 55 fibrinolytic therapy 55 HCV genotype 55 CCR5 antagonist 55 neoadjuvant chemotherapy 55 evaluating Vectibix 55 crizotinib PF # 55 non metastatic resectable 55 metastatic castrate resistant 55 completely resected 55 IIIa inhibitor 55 randomized placebo 55 Abciximab 55 randomized Phase 2b 55 Gliadel Wafer 55 induced macular edema 55 diagnosed Ph + 55 remission CR 55 Free Survival PFS 55 etoposide 55 mg/m2 administered 55 oral FTY# 55 Diabetic Macular Edema 55 Fludarabine 55 unresectable locally advanced 55 doxorubicin cyclophosphamide 55 investigational protease inhibitor 55 unresectable Stage III 55 observer blinded randomized 55 rituximab refractory 55 multiple myeloma MM 55 postmenopausal osteoporotic women 55 novel VDA molecule 55 elotuzumab 55 Matrix Phase 2b 55 BARACLUDE ® 55 Relapsed Multiple Myeloma 55 Acute Ischemic Stroke 55 sorafenib Nexavar 55 GAMMAGARD 55 5 FU leucovorin 55 Phase IIa 55 administered orally 55 dirucotide MBP# 55 CLARITY study 55 mCRC patients 55 oral deforolimus 55 subcutaneous dosing 55 NRTI backbone 55 systemic ALCL 55 IFN α 55 alefacept 55 EOquin TM 55 phase IIIb 55 subcutaneous SC 55 adefovir dipivoxil 55 mitoxantrone 55 HbA1c levels 55 CrCl 55 genotype 1a 55 relapsing remitting multiple sclerosis 55 Clinical Trial Evaluating 55 rFVIIa 55 tenofovir disoproxil fumarate 55 placebo controlled clinical trials 55 registrational Phase 55 adjunctive ABILIFY 55 endoscopic remission 55 venlafaxine XR 55 Multiple Ascending Dose 55 RECORD1 55 moderate renal impairment 55 rFSH 55 CR nPR 55 Phase IIb trial 55 tolerability 55 cisplatin chemotherapy 55 mg m² 55 Aptivus ® 55 CRp 54 TAXUS Express Stent 54 confirmatory Phase III 54 hemodialysis patients 54 bevacizumab Avastin 54 log# copies mL 54 relapsing remitting MS RRMS 54 evaluating Xcytrin 54 randomization 54 intravesical instillation 54 lenalidomide dexamethasone 54 ritonavir boosted protease inhibitor 54 sUA 54 BENICAR HCT 54 sustained virologic response 54 Phase 2a trial 54 catheter occlusion 54 pharmacokinetic PK 54 deferoxamine 54 tiotropium 54 NO# [002] 54 genotypic resistance 54 TPV r 54 aspartate aminotransferase AST 54 multicenter placebo controlled 54 MGd 54 lenalidomide Revlimid R 54 Parkinson disease levodopa induced 54 6 mercaptopurine 54 NOX E# 54 pharmacokinetic parameters 54 MIST II 54 mitomycin 54 azilsartan medoxomil 54 MAGE A3 ASCI 54 low dose dexamethasone 54 vapreotide acetate 54 mitoxantrone plus 54 BENICAR 54 omega interferon 54 5 Fluorouracil 54 HMG CoA reductase inhibitor 54 receiving prophylactic anticoagulation 54 bone marrow reticulin deposition 54 non squamous NSCLC 54 aspirin heparin 54 inhibitor RG# 54 Phase Ib IIa 54 timepoints 54 caspofungin 54 IAP inhibitor 54 II Clinical Trial 54 plus prednisone prednisolone 54 MADIT II 54 myelodysplastic myeloproliferative diseases 54 fluorouracil 54 PROMACTA 54 Cyclophosphamide 54 Apidra ® 54 low dose Iluvien 54 ALVESCO 54 Pred Forte 54 alkylating agent 54 Castration Resistant Prostate Cancer 54 relapsed CLL 54 T2DM 54 dexamethasone 54 goserelin 54 ZACTIMA 54 pamidronate 54 Teriflunomide 54 untreated multiple myeloma 54 liposomal doxorubicin 54 remission induction 54 oral iron chelator 54 EINSTEIN DVT 54 INFERGEN 54 cisplatin vinorelbine 54 oral antidiabetic medication 54 Phase 1b trial 54 mg simvastatin 54 autoantibody positive 54 Phase III Pivotal 54 FAME Study 54 chronic HCV infection 54 everolimus eluting stents 54 Engerix B 54 acute PAO 54 Study Evaluating 54 immunomodulatory therapy 54 Pegylated Liposomal Doxorubicin 54 Phase IIa trials 54 AZILECT R 54 vidofludimus 54 MIRAPEX 54 Capesaris 54 mg FV 54 administered intranasally 54 receiving VICTRELIS 54 Blinatumomab 54 relapsers 54 antibody MAb 54 eptifibatide 54 VFEND 54 abacavir Ziagen 54 Solid Tumors 54 IU ml 54 ADP receptor antagonist 54 #mg ATC 54 PD LID 54 tapentadol ER 54 titrated glipizide 54 Myelodysplastic Syndrome MDS 54 Navelbine ® 54 celgosivir 54 multinational multicenter randomized 54 INCB# [001] 54 carboplatin 54 lamivudine refractory patients 54 cytogenetic response 54 tinzaparin 54 HIV uninfected 54 Lamictal XR 54 EGFR HER2 54 palifermin 54 Xeloda ® 54 TKB# 54 recurrent glioblastoma 54 PEG Intron ® 54 HBeAg negative 54 ocular hypertension 54 preoperative chemotherapy 54 cetuximab Erbitux R 54 baminercept 54 MKC# MT 54 achieved sustained virologic 54 NNRTI 54 standard chemotherapy regimen 54 ascending dose study 54 DOXIL 54 rosuvastatin #mg 54 irinotecan chemotherapy 54 Akt inhibitor 54 autologous stem cell 54 urocortin 2 54 NovoTTF 54 valopicitabine 54 advanced hepatocellular carcinoma 54 gemcitabine cisplatin 54 acyclovir Lauriad R 54 Phase Ib study 54 amprenavir 54 Bortezomib 54 metastatic castration resistant 54 placebo controlled multicenter 54 Irinotecan 54 MVax R 54 specified primary endpoint 54 ethambutol 54 undetectable virus HCV 54 anthracycline taxane 54 maximally tolerated dose 54 Quinamed 54 -#.# log# copies mL 54 severe renal impairment 54 epirubicin 54 advanced metastatic renal 54 Ozarelix 54 YERVOY 54 noninferior 54 prospective observational 54 unstable angina UA 54 NATRECOR R 54 chemotherapy docetaxel 54 virus HCV protease inhibitor 54 Multicenter Randomized Double 54 peg interferon 54 Doxil ® 54 leukemia CLL 54 FEMALES SHOULD BE ADVISED 54 FluCAM 54 severe oral mucositis 54 ORENCIA ® 54 Phase IIb Trial 54 chronic ITP patients 54 Phase 2a clinical 54 administered cetrorelix 54 underwent surgical resection 54 secondary efficacy endpoints 54 pimecrolimus cream 54 previously untreated follicular 54 Platinol ® 54 lamivudine monotherapy 54 fluticasone furoate 54 elagolix 54 LB# [003] 54 CCX# B 54 eliglustat tartrate 54 AGILECT R 54 mapatumumab 54 interferon alfa 54 insulin lispro 54 LCP Tacro TM 54 refractory CTCL 54 investigational oral 54 beta 1a 54 CA4P 54 Ophena TM 54 tipranavir r 54 lintuzumab SGN 54 CIMZIA TM certolizumab pegol 54 epoetin alfa 54 hypogonadal men 54 CIMZIA ™ 54 oral methylnaltrexone 54 ISENTRESS 54 BCIRG 54 demonstrated clinically meaningful 54 pharmacodynamics PD 54 Intravitreal 54 retinal vein occlusion induced 54 infliximab 54 pemetrexed 53 Gemzar ® 53 CYT# potent vascular disrupting 53 laquinimod 53 Seliciclib 53 Refractory Hodgkin Lymphoma 53 Anti TNF 53 both intercalates DNA 53 epirubicin cyclophosphamide 53 cyclophosphamide doxorubicin vincristine 53 GSK# [001] 53 Patients Treated With 53 neratinib 53 achieved sustained virological 53 paclitaxel Taxol ® 53 IBS C 53 Pooled Analysis 53 O PPDS 53 Toxicities 53 ISTODAX ® 53 Acute Coronary Syndromes ACS 53 budesonide foam 53 Phase III pivotal 53 HBeAg positive patients 53 relapsed Hodgkin lymphoma 53 RG# ITMN 53 pegylated interferons 53 Prospective Randomized Trial 53 FIRMAGON 53 APPRAISE 53 XGEVA 53 intravesical infusion therapy 53 BENCHMRK 53 Neulasta ®